Cagrilintide is a long-acting amylin analogue in development for treating obesity and type 2 diabetes, often used in combination with semaglutide (CagriSema). It works by increasing feelings of fullness and slowing gastric emptying to reduce food intake. Common side effects, which are similar to those from semaglutide, include gastrointestinal issues like nausea, vomiting, and diarrhea, though these often decrease over time.
How Cagrilintide Works
Cagrilintide is a synthetic version of the hormone amylin and binds to amylin receptors in the brain to promote satiety and control appetite.
It also slows the rate at which food leaves your stomach, which helps regulate glucose levels and increases feelings of fullness.
Administration and Dosing
Cagrilintide is administered via a once-weekly subcutaneous injection under the skin.
In clinical trials, doses have ranged from 0.3 mg to 4.5 mg weekly, with mid-to-higher doses showing more promising weight loss results.
Common Side Effects
Gastrointestinal Issues:
The most common adverse events are digestive, including nausea, vomiting, constipation, and abdominal pain.
Dose-Dependent:
These side effects are often dose-dependent and tend to subside as the body adjusts to the medication.
Cagrilintide is a long-acting amylin analogue in development for treating obesity and type 2 diabetes, often used in combination with semaglutide (CagriSema). It works by increasing feelings of fullness and slowing gastric emptying to reduce food intake. Common side effects, which are similar to those from semaglutide, include gastrointestinal issues like nausea, vomiting, and diarrhea, though these often decrease over time.
How Cagrilintide Works
Cagrilintide is a synthetic version of the hormone amylin and binds to amylin receptors in the brain to promote satiety and control appetite.
It also slows the rate at which food leaves your stomach, which helps regulate glucose levels and increases feelings of fullness.
Administration and Dosing
Cagrilintide is administered via a once-weekly subcutaneous injection under the skin.
In clinical trials, doses have ranged from 0.3 mg to 4.5 mg weekly, with mid-to-higher doses showing more promising weight loss results.
Common Side Effects
Gastrointestinal Issues:
The most common adverse events are digestive, including nausea, vomiting, constipation, and abdominal pain.
Dose-Dependent:
These side effects are often dose-dependent and tend to subside as the body adjusts to the medication.
